Company intelligence / Profile preview

PharmassêtX

Louisville, Kentucky, United Statespharmaceutical-technology.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PharmassêtX has received FDA Orphan Drug Designation for its lead program, a high-purity, high-potency formulation of epigallocatechin gallate (EGCG), for the treatment of pouchitis. Clinical trials are planned to begin in 2025. There are currently no FDA-approved drugs for pouchitis, and the company aims to address this unmet need with evidence supporting safety and effectiveness from prior studies on EGCG[2].

Therapeutic areas: Gastroenterology
Modalities: Small moleculeNatural product derivative (epigallocatechin gallate)
Industry: Biotech

Drug pipeline

2 assets

PSX-514

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Clinical trial collaboration with an unnamed global leader is mentioned as planned but not yet specified[2].

Beyond the preview

Go deeper on PharmassêtX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmassêtX.

Explore the full profile